NITE Nightstar Therapeutics plc Sponsored ADR

Nightstar Therapeutics to Participate in Multiple Conferences in November

Nightstar Therapeutics to Participate in Multiple Conferences in November

WALTHAM, Mass. and LONDON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in the following investor conferences in November.

  • Jefferies London Healthcare Conference on Wednesday, November 14, 2018 at 12:40 p.m. GMT in London
  • Barclays Gene Editing & Gene Therapy Summit on Thursday, November 29, 2018 at 8:30 a.m. ET in New York City

The presentation at the Jefferies London Healthcare Conference will be webcast. To access the live webcast, please visit . A replay of the webcast will be available on the Nightstar website for two weeks following the conference.

About Nightstar

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar’s lead product candidate, NSR-REP1, is currently in Phase 3 development for the treatment of patients with choroideremia, a rare, degenerative, genetic retinal disorder that has no current treatments. Results from a Phase 1/2 trial of NSR-REP1 were published in  in 2018, in  in 2016, and in  in 2014. Nightstar’s second product candidate, NSR-RPGR, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease. In September 2018, Nightstar preliminary safety and efficacy data from the XIRIUS trial for the first five cohorts (combined n=15) of the dose escalation study at the EURETINA medical meeting.

For more information about Nightstar or its clinical trials, please visit .

Contact:

Senthil Sundaram, Chief Financial Officer

Brian Luque, Sr. Manager, Investor Relations

EN
08/11/2018

Underlying

NITENightstar Therapeutics plc Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nightstar Therapeutics plc Sponsored ADR

 PRESS RELEASE
Free
NITE Nightstar Thera...

Nightstar Therapeutics PLC Completion of Acquisition by Biogen

Nightstar Therapeutics PLC Completion of Acquisition by Biogen NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, June 07, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (“Nightstar”) is pleased to announce that, further to the announcement on 5 June 2019 that the High Court of Justice of England and Wales had sanctioned the scheme of arrangement, the Court Order has been deliver...

June 7, 2019 1 EN
 PRESS RELEASE
Free
NITE Nightstar Thera...

Nightstar Therapeutics plc Court Approval Received in Connection With...

Nightstar Therapeutics plc Court Approval Received in Connection With Acquisition by Biogen NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, June 05, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (“Nightstar”) is pleased to announce that the High Court of Justice of England and Wales today sanctioned the scheme of arrangement under Part 26 of the Companies Act pursuant to whic...

June 5, 2019 1 EN
 PRESS RELEASE
Free
NITE Nightstar Thera...

Nightstar Therapeutics plc Update to Timetable Relating to the Acquisi...

Nightstar Therapeutics plc Update to Timetable Relating to the Acquisition by Biogen NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, May 29, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (“Nightstar”) is pleased to announce an update to the expected timetable of events relating to the scheme of arrangement (the “Scheme”) pursuant to which Tungsten Bidco Limited, a newly-inc...

May 29, 2019 1 EN
 PRESS RELEASE
Free
NITE Nightstar Thera...

Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement ...

Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement for Acquisition By Biogen at General Meeting and Court Meeting Held on 8 May 2019 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, May 08, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") is pleased to announce that, at the General Meeting and the Court Meeting held earlier today in connection wi...

May 8, 2019 1 EN
 PRESS RELEASE
Free
NITE Nightstar Thera...

Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Nightstar S...

Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Nightstar Shareholders Vote “FOR” Proposed Acquisition by Biogen WALTHAM, Mass. and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") (NASDAQ: NITE) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended that Nightstar shareholders vote "FOR" the proposals relating to the proposed acquisition of Nightstar by an affiliate of Biogen Inc. (“Biogen”). To become effective, the transac...

April 26, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch